

# The Cost of 340B to Florida

*In 2025, workers and employers lost \$617 million in negotiated rebates to 340B*

Despite advocates' claims that the 340B program is free, it raises costs for patients, employers, state and local governments, Medicare, and managed Medicaid. One way it increases costs is by displacing the negotiated rebates that are used to lower net drug prices. Research by IQVIA shows that workers and employers lost \$14.5 billion in rebates nationally in 2025 due to 340B.<sup>1</sup> The cost to Florida workers and employers in 2025 was \$617 million.

## Cost of 340B to Florida workers and employers

| PER BENEFICIARY | PLAN TYPE                             | TOTAL COST    |
|-----------------|---------------------------------------|---------------|
| \$52            | Private sector employees <sup>2</sup> | \$553M        |
|                 | Government employees <sup>3</sup>     | \$64M         |
|                 | <b>Total</b>                          | <b>\$617M</b> |

340B also displaces rebates in managed Medicaid, which cost the state of Florida \$47M in 2025.

## Cost of 340B to Florida managed medicaid

| PER BENEFICIARY | STATE'S TOTAL COST |
|-----------------|--------------------|
| \$19            | \$47M              |

The cost of 340B to Florida has increased substantially in recent years due to program growth. From 2023 to 2025, the number of healthcare providers prescribing 340B drugs, the number of 340B facilities, and the value of 340B drug purchases all increased.

## 340B growth in Florida: 2023 to 2025

| 340B PRESCRIBERS |        | 340B FACILITIES <sup>4</sup> |        | 340B DRUG PURCHASES <sup>5</sup> |        |
|------------------|--------|------------------------------|--------|----------------------------------|--------|
| #                | GROWTH | #                            | GROWTH | #                                | GROWTH |
| 99,610           | +45%   | 3,140                        | +21%   | \$9.2 billion                    | +32%   |

Florida and neighboring states have lower than average 340B utilization, leaving substantial headroom for growth as large hospital systems and contract pharmacy networks continue to expand their footprint in the state.

## Florida vs. neighbors

| STATE             | 340B UTILIZATION <sup>6</sup> | COST PER BENEFICIARY |
|-------------------|-------------------------------|----------------------|
| FL                | 9%                            | \$52                 |
| GA                | 11%                           | \$66                 |
| AL                | 10%                           | \$60                 |
| <b>Total U.S.</b> | <b>14%</b>                    | <b>\$81</b>          |

1. The cost of 340B to states. IQVIA. 2026 (to appear).
2. Includes employer-sponsored plans and ACA health plans.
3. Includes state and local government employees.
4. Based on 340B "parent" facilities, not satellite sites or contract pharmacies.
5. 340B drug purchases at Wholesaler Acquisition Cost (WAC).
6. Percentage of 340B business by state, averaged over drug purchases and claims.